



Update on Italian Distribution Agreement

Perth, Australia & Malta - 21 August 2017 – Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), developer of quality medical solutions in the neuroscience space, has restructured the agreement with its Italian distributor, Service and Technology S.A.T Ltd (SAT, also known as Promosalute).

As noted in the March and June 2017 quarterly reports, Promosalute had not met its obligations to take *Mente Autism* units. Delivery and payment remains outstanding for 90 units.

Neurotech and Promosalute have agreed to vary the distribution agreement to commence in October 2017. This will require the remaining 90 units to be delivered over Q4 2017, with each order initiated upon receipt of a 50% upfront payment from Promosalute.

The distribution agreement continues to require Promosalute to place minimum orders and complete payment for *Mente Autism* units over an initial contract term to mid-2019, with the potential for extension beyond this.

Promosalute, through their consultants, continues to monitor the process for inclusion of neurofeedback therapy within the Italian Ministry of Health’s guidelines on the treatment and management of autism. If included, this would facilitate reimbursement for the cost of *Mente Autism* devices under the government’s social assistance system, which will assist with medical professional and neuropsychiatrists in prescribing *Mente Autism* as a therapy for their patients.

Promosalute has committed to establishing three autism centres across Italy, with the aim of generating awareness on the condition, introducing *Mente Autism* to parents of children on the autism spectrum, and to evaluate the suitability of *Mente Autism* for their child under the supervision of the centres’ medical professionals.

Italy continues to be an important target market for the Company, and Neurotech’s Board and management look forward to providing continued updates regarding the distribution of *Mente Autism* to this market.

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device *Mente Autism* and its associated platform,

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com

Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with ASD. Designed for home use, Mente Autism helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

For more information please contact:

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420